Navigation Links
Glide Pharma Completes £14.0 Million ($21.4 Million) Fundraising for Scale Up of Drug and Device Manufacturing Processes and Product Development

OXFORD, England, February 26, 2013 /PRNewswire/ --

Glide Pharma, the pharmaceutical development and device company focused on the needle-free administration of solid dose formulations, today announced that it has completed a £14.0 million ($21.4 million) investment round.  The fundraising was led by funds managed by Invesco Perpetual and supported by existing investors.  To date, Glide Pharma has successfully completed five funding rounds raising approximately £24.9 million.

Glide Pharma will use the funds to scale up the manufacturing process for its proprietary Glide SDI® solid dose injector system, including both the drug product and device. This includes the validation of an aseptic pilot-scale production line for clinical testing, and scale up for the manufacture of Glide SDI® device components.  The funds will also progress the development of the company's in-house programmes, which include epinephrine and parathyroid hormone.

"I am delighted to welcome Invesco Perpetual to Glide Pharma as an important new investor in this transformational fundraising.  This substantial investment round clearly demonstrates the confidence our shareholders have in our innovative technology, and its potential to revolutionise the delivery of therapeutics and vaccines," said Mark Kirby , Glide Pharma's Chairman.  "This fundraising follows recognition of Glide's novel technology by the UK government-backed Biomedical Catalyst scheme, which awarded the company £2.3 million funding for the development of a novel formulation of teriparatide (parathyroid hormone) for the treatment of osteoporosis."

The UK Biomedical Catalyst, which was announced by Prime Minister David Cameron in December 2011, is managed jointly by the Medical Research Council and the Technology Strategy Board.

About the Glide SDI® solid dose injector

The Glide SDI® is an innovative needle-free delivery system. The reusable injector uses a spring mechanism to administer a tiny solid dosage below the patient's skin, where it dissolves and releases the pharmaceutical. Glide's solid dose formulations eliminate the risk of needle-stick injuries and avoid time-consuming reconstitution. They also have the potential to modify the release of medicines and to improve stability, removing the need for refrigeration. The one-click action, pen-sized device is extremely easy to use, with medicines supplied in pre-filled disposable cassettes, making it ideal for self administration. In clinical testing, volunteers strongly preferred the Glide SDI® to traditional needle and syringe.

About Glide Pharma

Glide Pharma is a pharmaceutical development and device company focused on the easy, safe and convenient administration of solid dose formulations of therapeutics and vaccines. The company has a range of in-house and partnered programmes based on its proprietary solid dose injector, the Glide SDI®. Glide Pharma has a strong management team with extensive experience of the pharmaceutical, biotechnology and medical device sectors. The company has successfully completed five investment rounds, and is supported by a consortium of institutional and private technology investors, including Invesco Perpetual, Oxford Technology Venture Capital Trusts, Oxford Capital Partners and Hygea VCT.


Ian Smith
Chief Executive
Glide Pharma
Tel: +44-(0)8700-853-700

Rob Budge
RJB Communications
Tel: +44-(0)1865-760-969
Mobile: +44-(0)7710-741-241

SOURCE Glide Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Verathon, maker of GlideScope video laryngoscopes, provides free educational DVD to promote best practices in pediatric airway management.
2. TriReme Medical, Inc. Receives FDA Approval for Glider™ PTCA Catheter
3. CPhI in Partnership With PMI India Announces Pharma Project Management Conference
4. UBM Launches, an Online Peer-to-Peer Network for Pharmaceutical Industry Professionals
5. Alexza Pharmaceuticals Corporate Presentation to Be Webcast at Three Upcoming Investor Conferences
6. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Monday, March 4
7. ShangPharma Corporation Announces Extraordinary General Meeting of Shareholders
8. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
9. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2012 Financial Results on Thursday, March 7, 2013
10. Royalty Pharma Announces Proposal To Acquire Elan
11. Reckitt Benckiser Pharmaceuticals Inc. Receives FDA Response to Citizens Petition
Post Your Comments:
(Date:10/13/2015)... EDISON, N.J. , Oct. 13, 2015 /PRNewswire/ ... or the "Company"), a biopharmaceutical company focused on ... today announced the closing of its previously announced ... common stock and warrants to purchase up to ... a fixed combined price to the public of ...
(Date:10/13/2015)... 2015  Human Longevity, Inc. (HLI), the genomics-based, technology-driven ... today the launch of the company,s first Health Nucleus, ... potential to transform healthcare. The inaugural Health Nucleus is ... at HLI,s headquarters facility. More Health Nucleus facilities are ... International cities. --> ...
(Date:10/13/2015)... 2015  Measurement in accountable care programs is ... incentives, but gaps in measurement can result in ... systems. A new, peer-reviewed study published in ... explores measurement gaps for high-priority conditions and ... --> --> "These gaps ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 13, 2015 , ... Symposium Chairman, Dr. Rod J. Rohrich is pleased to ... be held March 2nd and 3rd, 2016. The annual meeting, along with the ... physicians from around the world. , Key topics at this year's event will include ...
(Date:10/13/2015)... ... 13, 2015 , ... Relay (, a technology company that ... significant contract that will provide its award-winning private messaging solution to Independence Blue ... success of its Relay program, IBX Wire™, which now has over 550,000 members ...
(Date:10/13/2015)... ... 13, 2015 , ... NavaFit Inc. today announced the launch of its NavaFit ... participate in local fitness & sporting events, and stay motivated. Users can ... costs drive us to get more serious about fitness and wellness, individuals are constantly ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Protein is ... the body, including muscle, bone, and blood. But how much protein does the average ... than it might seem, according to the October 2015 issue of Harvard Men's ...
(Date:10/13/2015)... ... 2015 , ... Scientists in Seattle and Vancouver compared the diagnostic value of ... mesothelioma. Surviving Mesothelioma has just posted an article on the new research. Click ... and the University of British Columbia found that certain genetic alterations were seen just ...
Breaking Medicine News(10 mins):